WHO approves China's Sinovac vaccine for emergency use

According to details, the global health organization has granted it approval saying that the vaccine prevented symptomatic disease in 51% cases, while severe symptoms and hospitalization was reduced in 100% of samples.

The emergency approval means the vaccine "meets international standards for safety, efficacy and manufacturing", the WHO said.

Some proofs and data gaps are still lacking though, WHO experts revealed.

Following the approval, Sinovac has become the second Chinese vaccine to receive the green light from the WHO. Earlier, Sinopharm was given approval by World Health Organization.

The approval opens the door for the jab to be used in the Covax program, which aims to ensure fair access to vaccines.

Sinovac, which has already been used in several countries including Pakistan and Brazil, has been recommended for people over 18. The second dose of this gap is administered after a gap of four weeks later.

A study in a Brazilian city saw a 95% decline in Covid-19 deaths after it vaccinated almost all of its adults with Sinovac.

One of Sinovac's main advantages is that it can be stored in a standard refrigerator at 2-8 degrees Celsius which makes it useful for the developing countries which might not be able to store large amounts of vaccine at low temperatures.